• Mohammed Alcharakh, Seongseok Yun, Yimin Dong, Nicole D Vincelette, Madiha Daud, Saima Manzoor, Irbaz Bin Riaz, and Faiz Anwer.
• Research Assistant, Hematology Department of Medicine, University of Arizona, AZ, USA.
• Immunotherapy. 2016 Jul 1; 8 (8): 847-52.

AbstractPost-stem cell transplantation (SCT) relapsed acute lymphoblastic leukemia (ALL) has extremely poor prognosis with median survival of less than 1 year. Donor lymphocyte infusion, second transplantation, chemotherapy or cytokine treatment have been tried as a salvage regimen without significant clinical benefit. Recently, blinatumomab, a bispecific monoclonal antibody targeting CD3-expressing T cells and CD19-expressing B-cell lineage malignant cells demonstrated promising outcomes in relapsed/refractory ALL patients. Literature on blinatumomab use in biphenotypic ALL along with Philadelphia chromosome positive (Ph(+)) ALL is limited. We report a case of post-SCT relapsed CD19 expressing biphenotypic lymphoblastic leukemia patient who achieved complete remission after blinatumomab treatment and has lasting remission for 1 year.

25 keywords...

hide…